Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome

In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) ( n =27) and steroid dependent nephrotic syndrome (SDNS) ( n =13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/m 2 /day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS.